PATENT CLAIM ANALYSIS

Application Number: 15975128
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "255000"]

Abstract:
The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R 101  and R 102  are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.

Claim (Index 1):
A pharmaceutical composition comprising a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R 101  and R 102  are each independently one of the following groups (1) to (32) and (40) to (50): (1) a phenyl group, (2) a pyridyl group, (3) a benzothienyl group, (4) an indolyl group, (5) a 2,3-dihydro-1H-indenyl group, (6) a naphthyl group, (7) a benzofuryl group, (8) a quinolyl group, (9) a thiazolyl group, (10) a pyrimidinyl group, (11) a pyrazinyl group, (12) a benzothiazolyl group, (13) a thieno[3,2-b]pyridyl group, (14) a thienyl group, (15) a cycloalkyl group, (16) a tetrahydropyranyl group, (17) a pyrrolyl group, (18) a 2,4-dihydro-1,3-benzodioxinyl group, (19) a 2,3-dihydrobenzofuryl group, (20) a 9H-fluorenyl group, (21) a pyrazolyl group, (22) a pyridazinyl group, (23) an indolinyl group, (24) a thieno[2,3-b]pyridyl group, (25) a thieno[3,2-d]pyrimidinyl group, (26) a thieno[3,2-e]pyrimidinyl group, (27) a 1H-pyrazolo[3,4-b]pyridyl group, (28) an isoquinolyl group, (29) a 2,3-dihydro-1,4-benzoxadinyl group, (30) a quinoxalinyl group, (31) a quinazolinyl group, (32) a 1,2,3,4-tetrahydroquinolyl group, (40) a 1,3-benzodioxolyl group, (41) a 2,3-dihydro-1,4-benzodioxinyl group, (42) a 3,4-dihydro-1,5-benzodioxepinyl group, (43) a dihydropyridyl group, (44) a 1,2-dihydroquinolyl group, (45) a 1,2,3,4-tetrahydroisoquinolyl group, (46) a benzoxazolyl group, (47) a benzoisothiazolyl group, (48) an indazolyl group, (49) a benzoimidazolyl group, and (50) an imidazolyl group, and each of the groups (1) to (32) and (40) to (50) may have one or more substituents selected from the following (1-1) to (1-37) on the cycloalkyl, aromatic or heterocyclic ring: (1-1) halogen atoms, (1-2) lower alkylthio groups optionally substituted with one or more halogen atoms, (1-3) lower alkyl groups optionally substituted with one or more halogen atoms, (1-4) lower alkoxy groups optionally substituted with one or more halogen atoms, (1-5) nitro group, (1-6) lower alkoxycarbonyl groups, (1-7) amino groups optionally substituted with one or two lower alkyl groups, (1-8) lower alkylsulfonyl groups, (1-9) cyano group, (1-10) carboxy group, (1-11) hydroxy group, (1-12) thienyl groups, (1-13) oxazolyl groups, (1-14) naphthyl groups, (1-15) benzoyl group, (1-16) phenoxy groups optionally substituted with one to three halogen atoms on the phenyl ring, (1-17) phenyl lower alkoxy groups, (1-18) lower alkanoyl groups, (1-19) phenyl groups optionally substituted on the phenyl ring with one to five substituents selected from the group consisting of halogen atoms, lower alkoxy groups, cyano group, lower alkanoyl groups and lower alkyl groups, (1-20) phenyl lower alkyl groups, (1-21) cyano lower alkyl groups, (1-22) 5 to 7-membered saturated heterocyclic group-substituted sulfonyl groups, the heterocyclic group containing on the heterocyclic ring one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, (1-23) thiazolyl groups optionally substituted with one or two lower alkyl groups on the thiazole ring, (1-24) imidazolyl groups, (1-25) amino lower alkyl groups optionally substituted with one or two lower alkyl groups on the amino group, (1-26) pyrrolidinyl lower alkoxy groups, (1-27) isoxazolyl groups, (1-28) cycloalkylcarbonyl groups, (1-29) naphthyloxy groups, (1-30) pyridyl groups, (1-31) furyl groups, (1-32) phenylthio group, (1-33) oxo group, (1-34) carbamoyl group, (1-35) 5 to 7-membered saturated heterocyclic groups containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the heterocyclic group optionally being substituted with one to three substituents selected from the group consisting of oxo group; lower alkyl groups; lower alkanoyl groups; phenyl lower alkyl groups; phenyl groups optionally substituted on the phenyl ring with one to three members selected from the group consisting of halogen atoms and lower alkoxy groups; and pyridyl groups, (1-36) oxido group and (1-37) lower alkoxido groups, with the proviso that R 101  and R 102  are not simultaneously unsubstituted phenyl, as an active ingredient, and pharmaceutically acceptable carrier or excipient.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 93.0
- Lexical Diversity: 1.59375
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15435084', '14300619', '13792971', '13298336', '11914183']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8079219094823711
- 35 USC 102 Novelty (BERT): 0.5877783665913543
- Combined Prediction Score: 0.7859075551932694
- Mean Citation Score: 493.381876
- Max Citation Score: 502.38043
- Similarity Product: 426.8038864398432

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test